Successfully Leverage Advances in Structural Biology, Computational Chemistry & Target Specificity to Discover Novel GPCR-Targeted Therapeutics Across High-Impact Disease Areas
Europe is experiencing a renaissance in GPCR-targeted drug discovery. The unprecedented commercial success of GLP-1 receptor agonists in obesity has reignited investment, innovation, and clinical exploration across the GPCR space. With major deals such as Eli Lilly’s $1.3 billion collaboration to advance small-molecule GPCR therapeutics using AI- and ML-powered platforms, momentum is building fast, making 2025 a pivotal year to be part of this rapidly evolving field.
Returning as the only meeting dedicated exclusively to GPCR drug discovery and development in Europe, the 2nd Annual GPCR-Targeted Drug Discovery Summit Europe brings together the brightest minds in biopharma to translate this momentum into actionable strategies.
From expanding pipelines in cardiometabolic disease, neuroscience, oncology and inflammation, to tackling biased signalling and optimising pharmacological modulation, this summit delivers the breadth and depth you need to progress differentiated, best-in-class GPCR-targeting drugs.
Whether you’re looking to identify new targets, enhance your discovery toolkit, or forge critical collaborations, this is your opportunity to stay ahead of the curve as biopharma redefines the druggable paradigm with next-generation GPCR therapeutics.
This meeting shares cutting-edge research and insights on GPCR-targeted drug discovery, which is crucial for advancing the field and potentially uncovering new therapeutic approaches.
Alexey Rak, Head of Bio Structure & Biophysics, Sanofi
The first GPCRs-Targeted Drug Discovery Summit was a success, stimulating valuable scientific exchange and networking. Its interactive format - featuring workshops, roundtable and panel discussions, and highly relevant presentations - was key. Since GPCRs continue to be a vital class of drug targets, this next summit is expected to be a rich source of insights in this fast-moving field.
Arne Rufer, Expert Scientist, Roche
Participating in this meeting provides a unique opportunity to discuss how next-generation targeted therapy modalities, including novel approaches to GPCR drug discovery, can open new perspectives in oncology. By bringing together scientific leaders and innovators, we can accelerate the translation of these advances into transformative treatments for patients with high unmet medical needs.
Manel Kraiem Merabet, Chief Development Officer, Skymab Biotherapeutics
Explore the Full Event Guide
- 60+ Attendees
- 18+ Speakers
- 16+ Data-driven Presentations
- 2 Interactive Workshops
- 1 Scientific Poster Session
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest industry trends and gain exclusive insights during our packed agenda, interactive roundtables and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.